Lasofoxifene (INN) (brand name Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.

CAS：180916-16-9
中文别名：(5R,6S)-5,6,7,8-四氢-6-苯基-5-(4-(2-(1-吡咯烷基)乙氧基)苯基)-2-萘酚;
英文别名：lasofoxifen;CP-336,156;
分子式：C28H31NO2
分子量：413.551
精确质量：413.235
Psa：32.7
Logp：5.6666

UNII：337G83N988

密度：1.15g/cm3
沸点：572.4ºC at 760mmHg
闪点：300ºC
折射率：1.613
蒸汽压：1.05E-13mmHg at 25°C